AstraZeneca has a solid presence in the Egyptian pharmaceutical market since 1968, when Astra opened its first office, followed by Zeneca Scientific in 1972. Today, AstraZeneca Egypt has around 400 employees, including the commercial operations and the manufacturing facility.
The AstraZeneca Egypt manufacturing facility is located in Sixth of October City. Inaugurated in 2006, the factory has the capacity to produce 400 million tablets and is currently operating 3 packing lines
AstraZeneca Egypt is engaged in the manufacture and supply of medicines that aim to make a real difference to the lives of Egyptians and the product range include Anastrozole, Rosuvastatin, Fulvestrant, Omeprazole, Meropenem etc. The business is driven by its mission to bring new innovative medicines into peoples lives, and the company is committed to working collaboratively, creatively, and with courage to achieve its goal of better health for patients.
Contact
AstraZeneca Egypt
133 – Road 90 North
5th Settlement New Cairo
Cairo Govornate
Egypt
Country President, Hatem Werdany, provides an overview of AstraZeneca’s 50+ year legacy in Egypt and outlines the company’s plans to launch up to 25 new products there over the next…
Khaled Atef Elmounayri, country manager of AstraZeneca Egypt, reveals how AstraZeneca has remained the fastest-growing multinational pharmaceutical company for five years straight in Egypt, despite facing economic difficulties and pricing…
After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years – starting in the UAE and expanding into Saudi…
See our Cookie Privacy Policy Here
